74 related articles for article (PubMed ID: 20709445)
1. Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1.
Fernández-Martínez AB; Bajo AM; Isabel Arenas M; Sánchez-Chapado M; Prieto JC; Carmena MJ
Cancer Lett; 2010 Dec; 299(1):11-21. PubMed ID: 20709445
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Prostate; 2009 May; 69(7):774-86. PubMed ID: 19189304
[TBL] [Abstract][Full Text] [Related]
3. Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398.
Fernández-Martínez AB; Bajo AM; Valdehita A; Isabel Arenas M; Sánchez-Chapado M; Carmena MJ; Prieto JC
Peptides; 2009 Dec; 30(12):2357-64. PubMed ID: 19772879
[TBL] [Abstract][Full Text] [Related]
4. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide (VIP) stimulates rat prostatic epithelial cell proliferation.
Juarranz MG; Bodega G; Prieto JC; Guijarro LG
Prostate; 2001 Jun; 47(4):285-92. PubMed ID: 11398176
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.
Fernández-Martínez AB; Collado B; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Mol Cell Endocrinol; 2007 May; 270(1-2):8-16. PubMed ID: 17434257
[TBL] [Abstract][Full Text] [Related]
7. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
8. Selection of cell lines with enhanced invasive phenotype from xenografts of the human prostate cancer cell line WPE1-NB26.
Rivette AS; Tokar EJ; Williams DE; Mackenzie CD; Ablin RJ; Webber MM
J Exp Ther Oncol; 2005; 5(2):111-23. PubMed ID: 16471037
[TBL] [Abstract][Full Text] [Related]
9. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice.
Rangon CM; Goursaud S; Medja F; Lelièvre V; Mounien L; Husson I; Brabet P; Jégou S; Janet T; Gressens P
J Pharmacol Exp Ther; 2005 Aug; 314(2):745-52. PubMed ID: 15872042
[TBL] [Abstract][Full Text] [Related]
10. Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model.
Collado B; Carmena MJ; Clemente C; Prieto JC; Bajo AM
Peptides; 2007 Sep; 28(9):1896-901. PubMed ID: 17544169
[TBL] [Abstract][Full Text] [Related]
11. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
12. VIP differentially activates beta2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPRL1.
El Zein N; Badran B; Sariban E
J Leukoc Biol; 2008 Apr; 83(4):972-81. PubMed ID: 18174366
[TBL] [Abstract][Full Text] [Related]
13. A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells.
Liu H; Chen A; Guo F; Yuan L
Cancer Lett; 2010 Sep; 295(1):27-37. PubMed ID: 20207476
[TBL] [Abstract][Full Text] [Related]
14. Cadmium-induced malignant transformation of human prostate epithelial cells.
Achanzar WE; Diwan BA; Liu J; Quader ST; Webber MM; Waalkes MP
Cancer Res; 2001 Jan; 61(2):455-8. PubMed ID: 11212230
[TBL] [Abstract][Full Text] [Related]
15. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
[TBL] [Abstract][Full Text] [Related]
16. Malignant transformation in a nontumorigenic human prostatic epithelial cell line.
Hayward SW; Wang Y; Cao M; Hom YK; Zhang B; Grossfeld GD; Sudilovsky D; Cunha GR
Cancer Res; 2001 Nov; 61(22):8135-42. PubMed ID: 11719442
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
18. VPAC receptor mediated tumor cell targeting by protamine based nanoparticles.
Ortner A; Wernig K; Kaisler R; Edetsberger M; Hajos F; Köhler G; Mosgoeller W; Zimmer A
J Drug Target; 2010 Jul; 18(6):457-67. PubMed ID: 20050817
[TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal peptide enhances wound healing and proliferation of human bronchial epithelial cells.
Guan CX; Zhang M; Qin XQ; Cui YR; Luo ZQ; Bai HB; Fang X
Peptides; 2006 Dec; 27(12):3107-14. PubMed ID: 16965837
[TBL] [Abstract][Full Text] [Related]
20. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.
García-Fernández MO; Collado B; Bodega G; Cortés J; Ruíz-Villaespesa A; Carmena MJ; Prieto JC
Gynecol Endocrinol; 2005 Jun; 20(6):327-33. PubMed ID: 16019382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
